Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA against PKR
- Development stage
- Preclinical
- Lead developer
- University of Florida
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
siRNA against PKR is a small interfering RNA (siRNA) designed to silence the expression of the Eukaryotic Translation Initiation Factor 2-Alpha Kinase 2 (EIF2AK2), commonly known as PKR. PKR is an interferon-inducible protein kinase that regulates protein synthesis and apoptosis in response to viral infection and cellular stress. In preclinical studies, particularly those conducted at the University of Florida, siRNA-mediated knockdown of PKR has been used to demonstrate that the loss of PKR function promotes leukemia progression by inhibiting apoptosis through the activation of Bcl-2 and reduction of PP2A activity. This agent is primarily utilized as a research tool to investigate the molecular mechanisms of hematological malignancies.
- Other names
- PKR siRNAsiRNA targeting PKREIF2AK2 siRNAEIF-2AK2 siRNAEIF 2AK2 siRNA
02
Targets
EIF2AK2 (Interferon-induced protein kinase R)PKR (Interferon-induced, double-stranded RNA-activated protein kinase)Pattern-recognition receptor sensing double-stranded RNA (dsRNA-sensing PRR)
Beyond the preview
Go deeper on siRNA against PKR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA against PKR.